NMRANeumora Therapeutics Inc. Common Stock

NAS · US · Healthcare · Biotechnology · neumoratx.com

1.630USD-0.61%Mkt Cap: 306.27M $P/E: —3d ago

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. Th…

Headline	Source	Time
Older
Neumora Therapeutics (NMRA) Stock Sees Fair Value Falls After Navacaprant Discontinuation	Simply Wall St.	Jul 11
Why Neumora Therapeutics, Inc. (NMRA) Is One of the Best Get Rich Quick Stocks to Buy	IInsider Monkey	Jul 7
LB Pharmaceuticals Inc. (LBRX) Maintains Buy Rating as Analyst Highlights LB-102 Potential	IInsider Monkey	Jul 2
Why Neumora Therapeutics (NMRA) Faces a Major Catalyst From Navacaprant’s Upcoming Depression Data	IInsider Monkey	Jun 17
Three pivotal MDD trial failures for Neumora lead to staffing cuts	Clinical Trials Arena	Jun 16
Neumora Stock Plunges 49% After Late-Stage Depression Drug Failure	Zacks	Jun 16
Neumora depression drug fails; EnGene to cut 50% of staff	BioPharma Dive	Jun 16
Sector Update: Healthcare Stocks Softer Late Afternoon	MMT Newswires	Jun 15
Sector Update: Healthcare Stocks Softer Monday Afternoon	MMT Newswires	Jun 15
NMRA Stock On Track For Worst Day In 1.5 Years — Neumora Therapeutics' Lead Depression Drug Fails Late Stage Trials	Stocktwits	Jun 15
Neumora Ends Depression Drug Programme and Announces Workforce Reduction (NMRA)	InvestorsHub	Jun 15

NMRANeumora Therapeutics Inc. Common Stock

Industry Peers